Extracellular matrix and cytochrome P450 gene expression can distinguish steatohepatitis from steatosis in mice

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 9, 2014, Pages 1762-1772

  Hennig, Ewa E ^a,b   Mikula, Michal ^b   Goryca, Krzysztof ^b   Paziewska, Agnieszka ^a   Ledwon, Joanna ^a   Nesteruk, Monika ^a   Woszczynski, Marek ^b   Walewska Zielecka, Bozena ^c   Pysniak, Kazimiera ^b   Ostrowski, Jerzy ^a,b  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cytochrome P450; Extracellular matrix; Liver; Mouse model; NAFLD; NASH; Obesity; Steatohepatitis; Steatosis; Transcriptomics

Indexed keywords

MUS;

CYTOCHROME P450; GLUCOSE BLOOD LEVEL; INSULIN; LIPID; TRANSCRIPTOME;

ANIMAL; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; DNA MICROARRAY; ENZYMOLOGY; EXTRACELLULAR MATRIX; FATTY LIVER; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; LIVER; MALE; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; BLOOD GLUCOSE; CYTOCHROME P-450 ENZYME SYSTEM; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FATTY LIVER; HUMANS; INSULIN; LIPIDS; LIVER; MALE; MICE, INBRED C57BL; MOLECULAR SEQUENCE ANNOTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84908249332     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12328     Document Type: Article

References (61)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221-31.
2. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11: 183-90.
3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005; 365: 1415-28.
4. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol. 2002; 90: 3G-10G.
5. Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010; 42: 320-30.
6. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28: 339-50.
7. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011; 332: 1519-23.
8. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40: 1387-95.
9. Bragoszewski P, Habior A, Walewska-Zielecka B, et al. Expression of genes encoding mitochondrial proteins can distinguish nonalcoholic steatosis from steatohepatitis. Acta Biochim Pol. 2007; 54: 341-8.
10. Starmann J, Fälth M, Spindelböck W, et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS ONE. 2012; 7: e46584.
11. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol. 2008; 23: 1635-48.
12. Kennedy AJ, Ellacott KLJ, King VL, et al. Mouse models of the metabolic syndrome. Dis Model Mech. 2010; 3: 156-66.
13. Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol. 2011; 2011: 351982.
14. Naik A, Košir R, Rozman D. Genomic aspects of NAFLD pathogenesis. Genomics. 2013; 102: 84-95.
15. Kim Y, Park T. DNA microarrays to define and search for genes associated with obesity. Biotechnol J. 2010; 5: 99-112.
16. Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol. 2008; 294: G1281-7.
17. Sharma MR, Polavarapu R, Roseman D, et al. Transcriptional networks in a rat model for nonalcoholic fatty liver disease: a microarray analysis. Exp Mol Pathol. 2006; 81: 202-10.
18. Xu C, Wang G, Hao Y, et al. Correlation analysis between gene expression profile of rat liver tissues and high-fat emulsion-induced nonalcoholic fatty liver. Dig Dis Sci. 2011; 56: 2299-308.
19. Nishida T, Tsuneyama K, Fujimoto M, et al. Spontaneous onset of nonalcoholic steatohepatitis and hepatocellular carcinoma in a mouse model of metabolic syndrome. Lab Invest. 2013; 93: 230-41.
20. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012; 52: 59-69.
21. Gornicka A, Morris-Stiff G, Thapaliya S, et al. Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. Antioxid Redox Signal. 2011; 15: 437-45.
22. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-21.
23. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94: 2467-74.
24. R Development Core Team. R: a language and environment for statistical computing. Vienna: The R Foundation for Statistical Computing; 2011.
25. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004; 5: R80.
26. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000; 28: 27-30.
27. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008; 24: 1547-8.
28. Mikula M, Rubel T, Karczmarski J, et al. Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. Funct Integr Genomics. 2011; 11: 215-24.
29. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3: RESEARCH0034.
30. Kamburov A, Stelzl U, Lehrach H, et al. The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res. 2013; 41: D793-800.
31. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013; 41: D808-15.
32. Ayala JE, Samuel VT, Morton GJ, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010; 3: 525-34.
33. Nesteruk M, Hennig EE, Mikula M, et al. Mitochondrial-related proteomic changes during obesity and fasting in mice are greater in the liver than skeletal muscles. Funct Integr Genomics. 2014; 14: 245-59.
34. Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective. Expert Rev Gastroenterol Hepatol. 2011; 5: 223-31.
35. Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev. 2011; 27: 419-24.
36. Yoneda M, Endo H, Mawatari H, et al. Gene expression profiling of non-alcoholic steatohepatitis using gene set enrichment analysis. Hepatol Res. 2008; 38: 1204-12.
37. Sreekumar R, Rosado B, Rasmussen D, et al. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology. 2003; 38: 244-51.
38. Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005; 25: 760-71.
39. Oh H-Y, Shin S-K, Heo H-S, et al. Time-dependent network analysis reveals molecular targets underlying the development of diet-induced obesity and non-alcoholic steatohepatitis. Genes Nutr. 2013; 8: 301-16.
40. Zhang Y, Baker SS, Baker RD, et al. Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. PLoS ONE. 2012; 7: e51131.
41. Sharma A, Bartell SM, Baile CA, et al. Hepatic gene expression profiling reveals key pathways involved in leptin-mediated weight loss in ob/ob mice. PLoS ONE. 2010; 5: e12147.
42. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998; 114: 842-5.
43. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444: 860-7.
44. Curat CA, Miranville A, Sengenès C, et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes. 2004; 53: 1285-92.
45. Lang K, Ratke J. Leptin and Adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal. 2009; 7: 27.
46. Orgel JPRO, Eid A, Antipova O, et al. Decorin core protein (decoron) shape complements collagen fibril surface structure and mediates its binding. PLoS ONE. 2009; 4: e7028.
47. Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol. 2010; 29: 248-53.
48. Winnemöller M, Schmidt G, Kresse H. Influence of decorin on fibroblast adhesion to fibronectin. Eur J Cell Biol. 1991; 54: 10-7.
49. Ferdous Z, Wei VM, Iozzo R, et al. Decorin-transforming growth factor- interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem. 2007; 282: 35887-98.
50. Baghy K, Iozzo RV, Kovalszky I. Decorin-TGFβ axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem. 2012; 60: 262-8.
51. Baghy K, Dezso K, László V, et al. Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest. 2011; 91: 439-51.
52. Xaus J, Comalada M, Cardó M, et al. Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27(Kip1) and p21(Waf1). Blood. 2001; 98: 2124-33.
53. Bolton K, Segal D, McMillan J, et al. Decorin is a secreted protein associated with obesity and type 2 diabetes. Int J Obes (Lond). 2008; 32: 1113-21.
54. Lee H-S, Sherley JL, Chen JJW, et al. EMP-1 is a junctional protein in a liver stem cell line and in the liver. Biochem Biophys Res Commun. 2005; 334: 996-1003.
55. Wadehra M, Forbes A, Pushkarna N, et al. Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium. Dev Biol. 2005; 287: 336-45.
56. Hofer-Warbinek R, Schmid JA, Mayer H, et al. A highly conserved proapoptotic gene, IKIP, located next to the APAF1 gene locus, is regulated by p53. Cell Death Differ. 2004; 11: 1317-25.
57. Arkan MC, Hevener AL, Greten FR, et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005; 11: 191-8.
58. Liang F-Q, Alssadi R, Morehead P, et al. Enhanced expression of glutathione-S-transferase A1-1 protects against oxidative stress in human retinal pigment epithelial cells. Exp Eye Res. 2005; 80: 113-9.
59. Romero L, Andrews K, Ng L, et al. Human GSTA1-1 reduces c-Jun N-terminal kinase signalling and apoptosis in Caco-2 cells. Biochem J. 2006; 400: 135-41.
60. Adnan H, Quach H, MacIntosh K, et al. Low levels of GSTA1 expression are required for Caco-2 cell proliferation. PLoS ONE. 2012; 7: e51739.
61. Romero L, Higgins MA, Gilmore J, et al. Down-regulation of alpha class glutathione S-transferase by interleukin-1beta in human intestinal epithelial cells (Caco-2) in culture. Drug Metab Dispos. 2002; 30: 1186-93.